Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
复制标题
DOI：
10.4103/aja202246
复制
发表时间：
2023-05
影响因子：
2.9
通讯作者：
Li XC
中科院分区：
文献类型：
--
作者：
Huang YB;Li WL;Sun M;Duan X;Wang YT;Zhang LX;Xin ZH;Yun ZF;Fan B;Li XC
Studies have investigated the effects of androgen deprivation therapy (ADT) use on the incidence and clinical outcomes of coronavirus disease 2019 (COVID-19); however, the results have been inconsistent. We searched the PubMed, Medline, Cochrane, Scopus, and Web of Science databases from inception to March 2022; 13 studies covering 84 003 prostate cancer (PCa) patients with or without ADT met the eligibility criteria and were included in the meta-analysis. We calculated the pooled risk ratios (RRs) with 95% confidence intervals (CIs) to explore the association between ADT use and the infection risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and severity of COVID-19. After synthesizing the evidence, the pooled RR in the SARS-CoV-2 positive group was equal to 1.17, and the SARS-CoV-2 positive risk in PCa patients using ADT was not significantly different from that in those not using ADT (P = 0.544). Moreover, no significant results concerning the beneficial effect of ADT on the rate of intensive care unit admission (RR = 1.04, P = 0.872) or death risk (RR = 1.23, P = 0.53) were found. However, PCa patients with a history of ADT use had a markedly higher COVID-19 hospitalization rate (RR = 1.31, P = 0.015) than those with no history of ADT use. These findings indicate that ADT use by PCa patients is associated with a high risk of hospitalization during infection with SARS-CoV-2. A large number of high quality studies are needed to confirm these results.
登录
查看更多内容
影响因子：
3.7
作者：
Duarte MBO;Leal F;Argenton JLP;Carvalheira JBC
通讯作者：
Carvalheira JBC
DOI：
10.1016/s2213-2600(21)00559-2
发表时间：
2022-03
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Burki TK
通讯作者：
Burki TK
DOI：
10.3390/medicina57101079
发表时间：
2021-10-09
期刊：
Medicina (Kaunas, Lithuania)
影响因子：
--
作者：
Caballero-García A;Pérez-Valdecantos D;Guallar P;Caballero-Castillo A;Roche E;Noriega DC;Córdova A
通讯作者：
Córdova A
DOI：
10.3390/diagnostics11020355
发表时间：
2021-02-20
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Ferro M;Musi G;Matei DV;Mistretta AF;Luzzago S;Cozzi G;Bianchi R;Di Trapani E;Cioffi A;Lucarelli G;Busetto GM;Del Giudice F;Russo GI;Di Mauro M;Porreca A;Renne G;Catellani M;Bottero D;Brescia A;Cordima G;de Cobelli O
通讯作者：
de Cobelli O
影响因子：
64.8
作者：
Al-Aly, Ziyad;Xie, Yan;Bowe, Benjamin
通讯作者：
Bowe, Benjamin